|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | BCLC策略:预后预测和治疗推荐2022版更新显示文摘2018版BCLC预后和治疗推荐策略发布后,肝细胞癌(简称HCC)的研究又取得了重大进展。本次更新基于肝癌各领域的研究进展结果。重点关注影响策略的重要研究进展。虽然近年的研究结果成绩斐然,但将其引入为临床医生和研究者提供行动依据的循证模型指南来说证据效力依然不够确切。本文对该问题进行分析,阐述了为HCC患者制定个体化治疗临床决策所需的批判性思维和专业知识。 | Reig M Forner A Rimola J Ferrer-Fabrega J Burrel M Garcia-Criado A Kelley RK Galle PR Mazzaferro V Salem R Sangro B Singal AG Vogel A Fuster J Ayuso C Bruix J 刘永凡(摘译) 崔笑(摘译) 耿小平(审校) | 2022 | 肝胆外科杂志2022，30，5： | 80 |
| 2 | Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma显示文摘Viral-mediated gene transfer of thymidine kinase ofherpes simplex virus (HSV-tk) has been used to confercytotoxic sensitivity to ganciclovir (GCV) in a variety oftnmor cells. HSV-tk converts GCV into a phosphorylatedcompound which is toxic for dividing cells by blockingDNA synthesis. Our previous study has shown | Miguel Idoate Roberto Bilbao Bruno Sangro Oscar Bruna Jesus Vazquez Jesus Prieto | 1997 | 中国实验血液学杂志1997，5，3： | 13 |
| 3 | Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions显示文摘 | Luigi Bolondi Andrew Burroughs Jean-Fran?ois Dufour Peter Galle Vincenzo Mazzaferro Fabio Piscaglia Jean Raoul Bruno Sangro | 2012 | Semin Liver Dis2012，，04： | 7 |
| 4 | Gene therapy of liver cancer显示文摘The application of gene transfer technologies to the treatment of cancer has led to the development of new experimental approaches like gene directed enzyme/pro- drug therapy (GDEPT), inhibition of oncogenes and restoration of tumor-suppressor genes. In addition, gene therapy has a big impact on other fields like cancer immunotherapy, anti-angiogenic therapy and virotherapy. These strategies are being evaluated for the treatment of primary and metastatic liver cancer and some of them have reached clinical phases. We present a review on the basis and the actual status of gene therapy approaches applied to liver cancer. | Ruben Hernandez-Alcoceba Bruno Sangro Jesus Prieto | 2006 | World Journal of Gastroenterology2006，12，38： | 6 |
| 5 | A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C显示文摘 | Bruno Sangro Carlos Gomez-Martin Manuel de la Mata Mercedes I?arrairaegui Elena Garralda Pilar Barrera Jose Ignacio Riezu-Boj Esther Larrea Carlos Alfaro Pablo Sarobe Juan José Lasarte Jose L. Pérez-Gracia Ignacio Melero Jesús Prieto | 2013 | Journal of Hepatology2013，，： | 6 |
| 6 | 接受纳武单抗治疗的晚期肝细胞癌患者炎症生物标志物与临床转归的相关性显示文摘【据Journal of Hepatology 2020年7月报道】题:接受纳武单抗治疗的晚期肝细胞癌患者炎症生物标志物与临床转归的相关性(作者Sangro B等)程序性死亡因子-1(PD-1)抑制剂纳武单抗治疗晚期肝细胞癌患者具有持久的疗效,较高的安全性,且能够显著提高患者的生存期。该研究回顾性分析了接受纳武单抗治疗的肝细胞癌患者的免疫生物学特征以及生物标志物和临床转归之间可能的相关性。 | 周豪 牛俊奇 SANGRO B MELERO I WADHAWAN S | 2020 | 临床肝胆病杂志2020，36，9： | 4 |
| 7 | SJWD15012600002640显示文摘 | Jens Ricke Karsten Bulla Frank Kolligs Markus Peck‐Radosavljevic Peter Reimer Bruno Sangro Eckart Schott Kerstin Schütte Chris Verslype Jerzy Walecki Peter Malfertheiner | 2015 | Liver Int2015，，2： | 3 |
| 8 | Long-term follow-up study of gastroduodenal lesions after radioembolization of hepatic tumors显示文摘AIM:To evaluate the long-term natural history of the gastroduodenal lesions secondary to extrahepatic embolization with Ytrium 90(90 Y) spheres.METHODS:From September 2003 to January 2012,379 procedures of liver radioembolization(RE) using resin microspheres loaded with 90 Y were performed in our center.We have retrospectively compiled the data from 379 RE procedures performed in our center.We report a comprehensive clinical,analytical,endoscopic and histologic long-term follow-up of a series of patients who developed gastroduodenal lesions after the treatment.RESULTS:Six patients(1.5%) developed gastrointestinal symptoms and had gastrointestinal lesions as shown by upper endoscopy in the next 12 wk after RE.The mean time between RE and the appearance of symptoms was 5 wk.Only one patient required endoscopic and surgical treatment.The incidence of gastrointestinal ulcerations was 3.75%(3/80) when only planar images were used for the pre-treatment evaluation.It was reduced to 1%(3/299) when singlephoton emission computed tomography(SPECT) images were also performed.The symptoms that lasted for a longer time were nausea and vomiting,until 25 mo after the treatment.CONCLUSION:All patients were free from severe symptoms at the end of follow-up.The routine use of SPECT has decreased the incidence of gastrointestinal lesions due to unintended deployment of 90 Y particles. | Iago Rodríguez-Lago Cristina Carretero Maite Herráiz José C Subtil Maite Betés Macarena Rodríguez-Fraile Jesús J Sola José I Bilbao Miguel Muoz-Navas Bruno Sangro | 2013 | World Journal of Gastroenterology2013，19，19： | 2 |
| 9 | Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization显示文摘 | J.-L. Raoul B. Sangro A. Forner V. Mazzaferro F. Piscaglia L. Bolondi R. Lencioni | 2010 | Cancer Treatment Reviews2010，，3： | 2 |
| 10 | Measurement of the integrated luminosity of the Phase 2 data of the Belle Ⅱ experiment显示文摘From April to July 2018,a data sample at the peak energy of the T(4 S) resonance was collected with the Belle Ⅱ detector at the SuperKEKB electron-positron collider.This is the first data sample of the Belle Ⅱ experiment.Using Bhabha and digamma events,we measure the integrated luminosity of the data sample to be(496.3±0.3±3.0) pb-1,where the first uncertainty is statistical and the second is systematic.This work provides a basis for future luminosity measurements at Belle Ⅱ. | F.Abudinén I.Adachi P.Ahlburg H.Aihara N.Akopov A.Aloisio F.Ameli L.Andricek N.Anh Ky D.M.Asner H.Atmacan T.Aushev V.Aushev T.Aziz K.Azmi V.Babu S.Baehr S.Bahinipati A.M.Bakich P.Bambade Sw.Banerjee S.Bansal V.Bansal M.Barrett J.Baudot A.Beaulieu J.Becker P.K.Behera J.V.Bennett E.Bernieri F.U.Bernlochner M.Bertemes M.Bessner S.Bettarini V.Bhardwaj F.Bianchi T.Bilka S.Bilokin D.Biswas G.Bonvicini A.Bozek M.Bračko P.Branchini N.Braun T.E.Browder A.Budano S.Bussino M.Campajola L.Cao G.Casarosa C.Cecchi D.Červenkov M.-C.Chang P.Chang R.Cheaib V.Chekelian Y.Q.Chen Y.-T.Chen B.G.Cheon K.Chilikin H.-E.Cho K.Cho S.Cho S.-K.Choi S.Choudhury D.Cinabro L.Corona L.M.Cremaldi S.Cunliffe T.Czank F.Dattola E.De La Cruz-Burelo G.De Nardo M.De Nuccio G.De Pietro R.de Sangro M.Destefanis S.Dey A.De Yta-Hernandez F.Di Capua S.Di Carlo J.Dingfelder Z.Doležal I.Domínguez Jiménez T.V.Dong K.Dort S.Dubey S.Duell S.Eidelman M.Eliachevitch T.Ferber D.Ferlewicz G.Finocchiaro S.Fiore A.Fodor F.Forti A.Frey B.G.Fulsom M.Gabriel E.Ganiev M.Garcia-Hernandez R.Garg A.Garmash V.Gaur A.Gaz U.Gebauer A.Gellrich J.Gemmler T.Geßler R.Giordano A.Giri B.Gobbo R.Godang P.Goldenzweig B.Golob P.Gomis P.Grace W.Gradl E.Graziani D.Greenwald C.Hadjivasiliou S.Halder K.Hara T.Hara O.Hartbrich K.Hayasaka H.Hayashii C.Hearty M.T.Hedges I.Heredia de la Cruz M.Hernández Villanueva A.Hershenhorn T.Higuchi E.C.Hill H.Hirata M.Hoek S.Hollitt T.Hotta C.-L.Hsu Y.Hu K.Huang T.Iijima K.Inami G.Inguglia J.Irakkathil Jabbar A.Ishikawa R.Itoh M.Iwasaki Y.Iwasaki S.Iwata P.Jackson W.W.Jacobs D.E.Jaffe E.-J.Jang H.B.Jeon S.Jia Y.Jin C.Joo J.Kahn H.Kakuno A.B.Kaliyar G.Karyan Y.Kato T.Kawasaki H.Kichimi C.Kiesling B.H.Kim C.-H.Kim D.Y.Kim S.-H.Kim Y.K.Kim Y.Kim T.D.Kimmel K.Kinoshita C.Kleinwort B.Knysh P.Kodyš T.Koga I.Komarov T.Konno S.Korpar D.Kotchetkov N.Kovalchuk T.M.G.Kraetzschmar P.Križan R.Kroeger J.F.Krohn P.Krokovny W.Kuehn T.Kuhr M.Kumar R.Kumar K.Kumara S.Kurz A.Kuzmin Y.-J.Kwon S.Lacaprara Y.-T.Lai C.La Licata K.Lalwani L.Lanceri J.S.Lange K.Lautenbach I.-S.Lee S.C.Lee P.Leitl D.Levit P.M.Lewis C.Li L.K.Li S.X.Li Y.M.Li Y.B.Li J.Libby K.Lieret L.Li Gioi J.Lin Z.Liptak Q.Y.Liu D.Liventsev S.Longo A.Loos F.Luetticke T.Luo C.MacQueen Y.Maeda M.Maggiora S.Maity E.Manoni S.Marcello C.Marinas A.Martini M.Masuda K.Matsuoka D.Matvienko J.McNeil J.C.Mei F.Meier M.Merola F.Metzner M.Milesi C.Miller K.Miyabayashi H.Miyata R.Mizuk G.B.Mohanty H.Moon T.Morii H.-G.Moser F.Mueller F.J.Müller Th.Muller R.Mussa K.R.Nakamura E.Nakano M.Nakao H.Nakayama H.Nakazawa M.Nayak G.Nazaryan D.Neverov M.Niiyama N.K.Nisar S.Nishida K.Nishimura M.Nishimura M.H.A.Nouxman B.Oberhof S.Ogawa Y.Onishchuk H.Ono Y.Onuki P.Oskin H.Ozaki P.Pakhlov G.Pakhlova A.Paladino T.Pang E.Paoloni H.Park S.-H.Park B.Paschen A.Passeri S.Patra S.Paul T.K.Pedlar I.Peruzzi R.Peschke R.Pestotnik M.Piccolo L.E.Piilonen P.L.M.Podesta-Lerma V.Popov C.Praz E.Prencipe M.T.Prim M.V.Purohit P.Rados M.Remnev P.K.Resmi I.Ripp-Baudot M.Ritter M.Ritzert G.Rizzo L.B.Rizzuto S.H.Robertson D.Rodríguez Pérez J.M.Roney C.Rosenfeld A.Rostomyan N.Rout G.Russo D.Sahoo Y.Sakai D.A.Sanders S.Sandilya A.Sangal L.Santelj P.Sartori Y.Sato V.Savinov B.Scavino M.Schram H.Schreeck J.Schueler C.Schwanda A.J.Schwartz B.Schwenker R.M.Seddon Y.Seino A.Selce K.Senyo M.E.Sevior C.Sfienti C.P.Shen H.Shibuya J.-G.Shiu A.Sibidanov F.Simon S.Skambraks R.J.Sobie A.Soffer A.Sokolov E.Solovieva S.Spataro B.Spruck M.Starič S.Stefkova Z.S.Stottler R.Stroili J.Strube M.Sumihama T.Sumiyoshi D.J.Summers W.Sutcliffe M.Tabata M.Takizawa U.Tamponi S.Tanaka K.Tanida H.Tanigawa N.Taniguchi Y.Tao P.Taras F.Tenchini E.Torassa K.Trabelsi T.Tsuboyama N.Tsuzuki M.Uchida I.Ueda S.Uehara T.Uglov K.Unger Y.Unno S.Uno P.Urquijo Y.Ushiroda S.E.Vahsen R.van Tonder G.S.Varner K.E.Varvell A.Vinokurova L.Vitale A.Vossen E.Waheed H.M.Wakeling K.Wan W.Wan Abdullah B.Wang M.-Z.Wang X.L.Wang A.Warburton M.Watanabe S.Watanuki J.Webb S.Wehle N.Wermes C.Wessel J.Wiechczynski P.Wieduwilt H.Windel E.Won S.Yamada W.Yan S.B.Yang H.Ye J.Yelton J.H.Yin M.Yonenaga Y.M.Yook C.Z.Yuan Y.Yusa L.Zani J.Z.Zhang Z.Zhang V.Zhilich Q.D.Zhou X.Y.Zhou V.I.Zhukova V.Zhulanov A.Zupanc | 2020 | Chinese Physics C2020，44，2： | 2 |
| 11 | Liver disease induced by radioembolization of liver tumors显示文摘 | SANGRO B GIL-ALZUGARAY B RODRIGUEZ J | 2008 | Cancer2008，112，7： | 1 |
| 12 | Efficacy and toxicity of intra- arterial cisplatin and etoposide for advanced hepatocellular carcinoma 显示文摘 | Sangro B Bios R Bilbao J | 2002 | Oncology2002，62，4： | 1 |
| 13 | Effectiveness of Lamivudine in treatment of acute recurrent hepatitis B after liver transplantation显示文摘 | Herrero JI Quiroga J Sangro B | 1998 | Dig Dis Sci1998，43，： | 1 |
| 14 | The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis显示文摘 | Rios R Sangro B Herrero I | 2005 | Am J Gastroenterol2005，100，： | 1 |
| 15 | Phase Ⅰ trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors显示文摘 | Sangro B Mazzolini G RuizJ | 2004 | J Clin Oncol2004，22，8： | 1 |
| 16 | Radioembolization forhepatocellular carcinoma显示文摘 | Sangro B Ifiarrairaegui M Bilbao JI | 2012 | J Hepatol2012，56，2： | 1 |
| 17 | Transarterial chemoembolization and radioembolization显示文摘 | Sangro B Salem R | 2014 | Semin Liver Dis2014，34，4： | 1 |
| 18 | Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance显示文摘 | Rocío García Garza Pablo Sarobe Juana Merino Juan J. Lasarte Delia D’Avola Virginia Belsue José A. Delgado Leyre Silva Mercedes I?arrairaegui Bruno Sangro Jesus J. Sola Fernando Pardo Jorge Quiroga J. Ignacio Herrero | 2013 | Liver Transpl2013，，9： | 1 |
| 19 | Phase Ⅰ trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors 显示文摘 | Sangro B Mazzolini G Ruiz J | 2004 | J Clin Oncol2004，22，8： | 1 |
| 20 | A clinckl trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C 显示文摘 | SANGRO B GOMEZ - MARTIN C DE LA MATA M | 2013 | J Hepatol2013，59，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员